observed

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…

3 days ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

1 week ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease

Event to be held October 14th at 4 p.m. EST October 09, 2025 07:00 ET  | Source: Gain Therapeutics, Inc.…

3 weeks ago

ACKO’s Grand Traffic Challan Report: Delhi Leads E Challan Fines

NEW DELHI, Oct. 6, 2025 /PRNewswire/ -- ACKO's Grand Traffic Challan Report gives a clear picture of how Indian motorists…

3 weeks ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

1 month ago

HelloFresh Reaffirms Commitment to Fighting Food Insecurity During Hunger Action Month

HelloFresh and its partners celebrate 10 million meals donated through Meals with Meaning, a program launched in 2020.NEW YORK--(BUSINESS WIRE)--This…

1 month ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

June 21, 2025 18:00 ET  | Source: BioAge Labs, Inc. Treatment with apelin receptor agonist enhanced glycemic control and demonstrated…

4 months ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

4 months ago